IGF2BP3 Expression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma

Akiyuki Wakita; Satoru Motoyama; Yusuke Sato; Yushi Nagaki; Hiromu Fujita; Kaori Terata; Kazuhiro Imai; Eri Maeda; Yoshihiro Minamiya

doi:10.1016/j.jss.2020.10.024

IGF2BP3 Expression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma

J Surg Res. 2021 Mar:259:137-144. doi: 10.1016/j.jss.2020.10.024. Epub 2020 Dec 3.

Authors

Akiyuki Wakita¹, Satoru Motoyama², Yusuke Sato², Yushi Nagaki², Hiromu Fujita², Kaori Terata², Kazuhiro Imai², Eri Maeda³, Yoshihiro Minamiya²

Affiliations

¹ Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan. Electronic address: wakita@gipc.akita-u.ac.jp.
² Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
³ Department of Environmental Health Science and Public Health, Akita University Graduate School of Medicine, Akita, Japan.

PMID: 33279839
DOI: 10.1016/j.jss.2020.10.024

Abstract

Background: Insulin-like growth factor-II mRNA binding protein 3 (IGF2BP3) is an oncofetal RNA-binding protein normally involved in cell growth and migration during the early stages of embryogenesis. However, it is also expressed in various cancers, and the relationship between IGF2BP3 and the clinicopathological features and prognosis of esophageal squamous cell carcinoma patients is not fully understood. Our aim in this study was to determine whether IGF2BP3 expression status correlates with prognosis in patients with advanced thoracic esophageal squamous cell carcinoma.

Methods: The IGF2BP3 expression statuses of 177 patients treated with esophagectomy without preoperative therapy were evaluated immunohistochemically using tissue microarray analysis. The relationships between IGF2BP3 expression status and clinicopathological features and survival were then assessed using appropriate statistics.

Results: Among 177 esophageal tumors, 122 (68.9%) expressed high levels of IGF2BP3. In patients undergoing surgery alone, IGF2BP3-high expression was significantly associated with a poorer prognosis. By contrast, there were no significant associations between IGF2BP3 expression and clinicopathological features or outcomes in patients treated with surgery plus postoperative adjuvant chemotherapy.

Conclusions: IGF2BP3 positivity in advanced thoracic esophageal squamous cell carcinoma is associated with adverse clinical outcomes in patients treated with surgery alone.

Keywords: Esophageal cancer; IGF2BP3; Prognosis; Survival.

MeSH terms

Adult
Age Factors
Aged
Aged, 80 and over
Biomarkers, Tumor / analysis
Biomarkers, Tumor / metabolism*
Chemotherapy, Adjuvant / statistics & numerical data
Clinical Decision-Making / methods
Disease-Free Survival
Esophageal Neoplasms / diagnosis
Esophageal Neoplasms / mortality*
Esophageal Neoplasms / pathology
Esophageal Neoplasms / therapy
Esophageal Squamous Cell Carcinoma / diagnosis
Esophageal Squamous Cell Carcinoma / mortality*
Esophageal Squamous Cell Carcinoma / pathology
Esophageal Squamous Cell Carcinoma / therapy
Esophagectomy
Esophagus / pathology
Esophagus / surgery
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local / epidemiology*
Neoplasm Recurrence, Local / etiology
Neoplasm Recurrence, Local / prevention & control
Neoplasm Staging
Prognosis
RNA-Binding Proteins / analysis
RNA-Binding Proteins / metabolism*
Risk Assessment / methods
Risk Factors
Tissue Array Analysis

Substances

Biomarkers, Tumor
IGF2BP3 protein, human
RNA-Binding Proteins